In the American Journal of Respiratory and Critical Care Medicine Lindsey te Brake and colleagues described the shortcomings of a moderate increase in rifampicin dosing, the cornerstone TB drug.Combined with ongoing trials to optimize the dose of rifampicin ≥35 mg/kg, powerful statistical pooled data analyses will help influence future treatment guidelines and improve the lives of millions of patients with tuberculosis worldwide.
Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
Te Brake LHM, Boeree MJ, Aarnoutse RE.
Lindsey te Brake, Martin Boeree and Rob Aarnoutse are members of theme Infectious diseases and global health.
Related news items
Step-up approach vs open necrosectomy for necrotizing pancreatitis18 April 2019
Another publication of the successful Dutch collaborative group on pancreatitis research with substantial contribution from Radboudumc researchers, Harry van Goor and Kees van Laarhoven.read more
Prophylactic antibiotics reduce hospitalisations and cost in head and neck cancer patients18 April 2019
In European journal of cancer Janneke Ham and colleagues showed that prophylactic antibiotics in locally advanced head and neck cancer patients treated with chemoradiotherapy did not reduce the incidence of (aspiration) pneumonias, but did reduce hospitalisations and tended to be cost-effective.read more
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.read more
ESCMID award for groundbreaking studies on NTM disease18 April 2019
Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.read more
EU funded project BIOMAP led by Ellen van den Bogaard12 April 2019
Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.read more